Serum Visfatin Levels in Women with Newly Diagnosed Polycystic Ovarian Disease: A Cross-Sectional Study
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Background: Polycystic ovarian disease (PCOD) is a common endocrine disorder frequently associated with insulin resistance and metabolic dysfunction. Visfatin, a visceral adipocytokine, has been implicated in inflammation and glucose regulation. Aim: To determine Serum Visfatin levels in newly diagnosed PCOD women and assess its relationship with body mass index (BMI). Methods: A cross-sectional study was conducted involving 80 women (40 PCOD; 40 healthy controls). Anthropometric, hormonal, glycemic, insulin resistance index, and serum Visfatin levels were measured. Results: Serum Visfatin was significantly increased in PCOD cases (39.25 ± 16.49 ng/mL) compared to controls (27.90 ± 8.21; p = 0.004). PCOD women also had significantly elevated LH, LH/FSH ratio, fasting glucose, insulin, and HOMA-IR (p < 0.001). Conclusion: Serum Visfatin is significantly elevated in PCOD and correlates with metabolic dysfunction. It may serve as an early biomarker for insulin resistance and cardiometabolic risk in PCOD. Key words: PCOD, Visfatin, HOMA-IR, Insulin Resistance, Adipocytokines
Fields of Study & Subjects
Ovarian function and disorders
Adipokines
Inflammation
and Metabolic Diseases
Diabetes
Cardiovascular Risks
and Lipoproteins
Publication details
- Journal / source
- International Journal of Health Sciences and Research
- Pages
- 220–220
- Publication date
- 25 March 2026
- Language
- EN